Jennifer Thurmon


Presentations

Secukinumab Maintains Superiority Over Ustekinumab in Clearing Skin and Improving Quality of Life in Patients With Moderate to Severe Plaque Psoriasis: 52-Week Results From CLARITY 09 October 2019 00:00 - 00:00